Dapagliflozin improves outcomes in HFmrEF and HFpEF

被引：0
|
作者：
Fernandez-Ruiz, Irene
机构：
[1] Nature Reviews Cardiology,
来源：
NATURE REVIEWS CARDIOLOGY | 2022年 / 19卷 / 11期
关键词：
D O I：
10.1038/s41569-022-00782-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In patients with heart failure (HF) with mildly reduced or preserved ejection fraction, the SGLT2 inhibitor dapagliflozin reduces the risk of worsening HF or cardiovascular death by 18%, reduces total HF events and cardiovascular deaths by 23% and improves HF symptoms, according to findings from the DELIVER trial.
引用
收藏
页码：719 / 719
页数：1
相关论文
共 50 条
  • [21] Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved
    Huynh, Karina
    NATURE REVIEWS CARDIOLOGY, 2021, 18 (11) : 737 - 737
  • [22] Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved
    Karina Huynh
    Nature Reviews Cardiology, 2021, 18 : 737 - 737
  • [23] The association between HFpEF and HFmrEF with mortality in Hospital Tengku Ampuan Rahimah, Klang
    Tan, M. M.
    Yunus, N. A. Mohd
    Mansor, N.
    Ramli, N. Q. Nik
    Rahim, N. A. Abdul
    Leong, L. Y.
    Seng, A. N. L. C.
    Subramaniam, K. G.
    Ang, S. Y.
    Ng, G. P. L.
    Ab Jalil, S.
    Mageswaren, E.
    Chee, K. H.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 393
  • [24] The importance of the NTproBNP rule-in criteria in the early diagnosis of HFmrEF and HFpEF
    Szabo, M. Marta
    Muk, B.
    Majoros, Z. S.
    Vagany, D.
    Kosa, K.
    Borsanyi, T.
    Dekany, M.
    Kiss, R. G.
    Nyolczas, N.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 433 - 433
  • [25] Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF
    Peikert, Alexander
    Bart, Bradley A.
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Kulac, Ian J.
    Kosiborod, Mikhail N.
    Desai, Akshay S.
    Jhund, Pardeep S.
    Lam, Carolyn S. P.
    Inzucchi, Silvio E.
    Martinez, Felipe A.
    de Boer, Rudolf A.
    Hernandez, Adrian F.
    Shah, Sanjiv J.
    Petersson, Magnus
    Langkilde, Anna Maria
    McMurray, John J. V.
    Solomon, Scott D.
    Vardeny, Orly
    JACC-HEART FAILURE, 2024, 12 (04) : 631 - 644
  • [26] Biomarkers of fibrosis, inflammation, renal dysfunction and its correlations in patients with HFpEF and HFmrEF
    Medvedeva, E. A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 304 - 304
  • [27] Functional mitral regurgitation in pts with HFrEF, HFmrEF and HFpEF: the good, the bad and the ugly ?
    Castelein, T.
    Beles, M.
    Verstreken, S.
    Goethals, M.
    Heggermont, W.
    Dierckx, R.
    Bartunek, J.
    Vanderheyden, M. Marc
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 41 - 41
  • [28] Functional mitral regurgitation in pts with HFrEF, HFmrEF and HFpEF: the good, the bad and the ugly?
    Vanderheyden, Marc
    Castelein, Thomas
    Bartunek, Jozef
    Beles, Monika
    Penicka, Martin
    Goethals, Marc
    Verstreken, Sofie
    Dierckx, Riet
    Heggermont, Ward
    ACTA CARDIOLOGICA, 2019, 74 : 32 - 32
  • [29] Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF
    Savarese, Gianluigi
    Orsini, Nicola
    Hage, Camilla
    Vedin, Ola
    Cosentino, Francesco
    Rosano, Giuseppe M. C.
    Dahlstrom, Ulf
    Lund, Lars H.
    JACC-HEART FAILURE, 2018, 6 (03) : 246 - 256
  • [30] 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF Results From REDUCE LAP-HF II
    Gustafsson, Finn
    Petrie, Mark C.
    Komtebedde, Jan
    Swarup, Vijendra
    Winkler, Sebastian
    Hasenfuss, Gerd
    Borlaug, Barry A.
    Mohan, Rajeev C.
    Flaherty, James D.
    Sverdlov, Aaron L.
    Fail, Peter S.
    Chung, Eugene S.
    Lurz, Philipp
    Lilly, Scott
    Kaye, David M.
    Cleland, John G. F.
    Cikes, Maja
    Leon, Martin B.
    Cutlip, Donald E.
    van Veldhuisen, Dirk J.
    Solomon, Scott D.
    Shah, Sanjiv J.
    JACC-HEART FAILURE, 2024, 12 (08) : 1425 - 1438
12345